Drug
Linsitinib clinical trials
Also written OSI-906 and OSI-906AA.
- studies test it
- 26
- open now
- 2
- in phase 3
- 4
- first study started
- 2007
Keep track of what changes. Save the linsitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 17
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 13
Astellas Pharma Inc (8) · Sling Therapeutics, Inc. (3) · National Cancer Institute (NCI) (3) · Astellas Pharma Global Development, Inc. (2) · Emory University (2) · SCRI Development Innovations, LLC (1) · University of Oxford (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Erlotinib (5) · Paclitaxel (2) · Everolimus (1) · Bortezomib (1) · Dexamethasone (1) · Sorafenib (1) · Irinotecan (1) · Pemetrexed (1)
Studies
Open first, then newest update. How each study uses linsitinib is read from its arms, and is right about nine times in ten.
Testing it · 26
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)RecruitingPhase 3Sling Therapeutics, Inc.NCT07753603Written as linsitinib
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)RecruitingPhase 2/3Sling Therapeutics, Inc.NCT06112340Written as linsitinib
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)CompletedPhase 2/3Sling Therapeutics, Inc.NCT05276063Written as Linsitinib
- Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedPhase 2Astellas Pharma IncNCT01186861Written as OSI-906
- Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) GeneCompletedPhase 2Astellas Pharma IncNCT01221077Written as OSI-906
- A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)CompletedPhase 1/2Astellas Pharma IncNCT00889382Written as OSI-906
- A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaCompletedPhase 3Astellas Pharma IncNCT00924989Written as OSI-906
- A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialCompletedPhase 2Astellas Pharma Global Development, Inc.NCT02057380Written as linsitinib
- Study of Intermittent OSI-906 DosingCompletedPhase 1Astellas Pharma IncNCT00514306Written as OSI-906
- Study of Continuous OSI-906 DosingCompletedPhase 1Astellas Pharma IncNCT00514007Written as OSI-906
- A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)CompletedPhase 1Astellas Pharma IncNCT00739453Written as OSI-906
- A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCCTerminatedPhase 2Astellas Pharma IncNCT01101906Written as OSI-906
- A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the BodyCompletedPhase 1Astellas Pharma Global Development, Inc.NCT01529684Written as OSI-906
- Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal CancerCompletedPhase 1SCRI Development Innovations, LLCNCT01154335Written as OSI-906
- Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaCompletedPhase 2University of OxfordNCT02546544Written as Linsitinib
- Linsitinib in Treating Patients With Gastrointestinal Stromal TumorsCompletedPhase 2National Cancer Institute (NCI)NCT01560260Written as Linsitinib
- A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedPhase 1/2University Health Network, TorontoNCT01672736Written as ASP7487, Velcade, Dexamethasone
- A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular CancerTerminatedPhase 2Emory UniversityNCT01334710Written as Sorafenib and OSI-906
- Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung CancerCompletedPhase 2National Cancer Institute (NCI)NCT01533181Written as Linsitinib
- Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01533246Written as linsitinib
See all 26 studies that test linsitinib →
Given in every arm · 1 — linsitinib is usual care beside what is tested
Codes
What other systems call linsitinib · ClinicalTrials.gg INT005685
- UNII (FDA) 15A52GPT8TLINSITINIBConfirmed FDA, Wikidata
- Wikidata Q6554803linsitinibConfirmed FDA, Wikidata
- NCI Thesaurus C70982LinsitinibOne source FDA
- DrugBank DB06075One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 15A52GPT8T | LINSITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q6554803 | linsitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C70982 | Linsitinib | One source FDA |
| DrugBank | DB06075 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.